Literature DB >> 28125105

Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.

Xuefeng Liu1,2, Ewa Krawczyk1,2, Frank A Suprynowicz1,2, Nancy Palechor-Ceron1,2, Hang Yuan1,2, Aleksandra Dakic1,2, Vera Simic1,2, Yun-Ling Zheng3, Praathibha Sripadhan1,2, Chen Chen1,2, Jie Lu1,2, Tung-Wei Hou1,2, Sujata Choudhury1,2, Bhaskar Kallakury1,2, Dean G Tang4, Thomas Darling5, Rajesh Thangapazham5, Olga Timofeeva3,6, Anatoly Dritschilo6, Scott H Randell7, Christopher Albanese1,2,3, Seema Agarwal1,2, Richard Schlegel1,2.   

Abstract

Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue. However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of translational research, including drug discovery and drug target identification. This protocol describes conditional reprogramming (CR), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the presence of a Rho kinase inhibitor (Y-27632). CR cells can be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft studies. The method requires a pathologist to differentiate healthy tissue from tumor tissue, and basic tissue culture skills. The protocol can be used with cells derived from both fresh and cryopreserved tissue samples. As approximately 1 million cells can be generated in 7 d, the technique is directly applicable to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the capacity to become fully differentiated when placed into conditions that mimic their natural environment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28125105      PMCID: PMC6195120          DOI: 10.1038/nprot.2016.174

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  51 in total

Review 1.  Issues to be considered when studying cancer in vitro.

Authors:  Beata Cunderlíková
Journal:  Crit Rev Oncol Hematol       Date:  2012-07-21       Impact factor: 6.312

Review 2.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 3.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

4.  An ecosystem of cancer cell line factories to support a cancer dependency map.

Authors:  Jesse S Boehm; Todd R Golub
Journal:  Nat Rev Genet       Date:  2015-06-16       Impact factor: 53.242

Review 5.  Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

Authors:  Jonathan D Boone; Zachary C Dobbin; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2015-05-27       Impact factor: 5.482

6.  Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.

Authors:  Lincoln D Nadauld; Sarah Garcia; Georges Natsoulis; John M Bell; Laura Miotke; Erik S Hopmans; Hua Xu; Reetesh K Pai; Curt Palm; John F Regan; Hao Chen; Patrick Flaherty; Akifumi Ootani; Nancy R Zhang; James M Ford; Calvin J Kuo; Hanlee P Ji
Journal:  Genome Biol       Date:  2014-08-27       Impact factor: 17.906

7.  Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.

Authors:  Guido Veit; Kathryn Oliver; Pirjo M Apaja; Doranda Perdomo; Aurélien Bidaud-Meynard; Sheng-Ting Lin; Jingyu Guo; Mert Icyuz; Eric J Sorscher; John L Hartman; Gergely L Lukacs
Journal:  PLoS Biol       Date:  2016-05-11       Impact factor: 8.029

8.  CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18.

Authors:  H W Chu; C Rios; C Huang; A Wesolowska-Andersen; E G Burchard; B P O'Connor; T E Fingerlin; D Nichols; S D Reynolds; M A Seibold
Journal:  Gene Ther       Date:  2015-07-02       Impact factor: 5.250

9.  Rapid Expansion of Human Epithelial Stem Cells Suitable for Airway Tissue Engineering.

Authors:  Colin R Butler; Robert E Hynds; Kate H C Gowers; Dani Do Hyang Lee; James M Brown; Claire Crowley; Vitor H Teixeira; Claire M Smith; Luca Urbani; Nicholas J Hamilton; Ricky M Thakrar; Helen L Booth; Martin A Birchall; Paolo De Coppi; Adam Giangreco; Christopher O'Callaghan; Sam M Janes
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

10.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440

View more
  101 in total

1.  Long-term culture and characterization of patient-derived primary hepatocytes using conditional reprogramming.

Authors:  Shan Su; Cristina Di Poto; Rabindra Roy; Xuefeng Liu; Wanxing Cui; Alexander Kroemer; Habtom W Ressom
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-11

2.  Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.

Authors:  Rashid Gabbasov; I Daniel Benrubi; Shane W O'Brien; John J Krais; Neil Johnson; Samuel Litwin; Denise C Connolly
Journal:  Cancer Biol Ther       Date:  2019-03-30       Impact factor: 4.742

3.  Conditionally reprogrammed macaque endocervical cells retain steroid receptor expression and produce mucus.

Authors:  Leo Han; Walker Andrews; Karsten Wong; Jeffrey T Jensen
Journal:  Biol Reprod       Date:  2020-05-26       Impact factor: 4.285

4.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

Review 5.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

6.  Mometasone absorption in cultured airway epithelium.

Authors:  Tuong T Nguyen; Paul S Soma; Teresa Mascenik; Catherine A Lewis; Rhianna E Lee; Brian D Thorp; Adam M Zanation; Charles S Ebert; Brent A Senior; Scott H Randell; Brandie M Ehrmann; Adam J Kimple
Journal:  Int Forum Allergy Rhinol       Date:  2019-10-21       Impact factor: 3.858

7.  The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Authors:  Erika Parasido; George S Avetian; Aisha Naeem; Garrett Graham; Michael Pishvaian; Eric Glasgow; Shaila Mudambi; Yichien Lee; Chukwuemeka Ihemelandu; Muhammad Choudhry; Ivana Peran; Partha P Banerjee; Maria Laura Avantaggiati; Kirsten Bryant; Elisa Baldelli; Mariaelena Pierobon; Lance Liotta; Emanuel Petricoin; Stanley T Fricke; Aimy Sebastian; Joseph Cozzitorto; Gabriela G Loots; Deepak Kumar; Stephen Byers; Eric Londin; Analisa DiFeo; Goutham Narla; Jordan Winter; Jonathan R Brody; Olga Rodriguez; Chris Albanese
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

8.  Mutation-specific downregulation of CFTR2 variants by gating potentiators.

Authors:  Radu G Avramescu; Yukari Kai; Haijin Xu; Aurélien Bidaud-Meynard; Andrea Schnúr; Saul Frenkiel; Elias Matouk; Guido Veit; Gergely L Lukacs
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

9.  Establishment of ornithine transcarbamylase deficiency-derived primary human hepatocyte with hepatic functions.

Authors:  Shan Su; Cristina Di Poto; Alexander H Kroemer; Wanxing Cui; Rabindra Roy; Xuefeng Liu; Habtom W Ressom
Journal:  Exp Cell Res       Date:  2019-09-09       Impact factor: 3.905

10.  Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.

Authors:  Timothy A Dinh; Ramja Sritharan; F Donelson Smith; Adam B Francisco; Rosanna K Ma; Rodica P Bunaciu; Matt Kanke; Charles G Danko; Andrew P Massa; John D Scott; Praveen Sethupathy
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.